Cargando…

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets

Cholesterol is an essential substance in mammalian cells, and cholesterol metabolism plays crucial roles in multiple biological functions. Dysregulated cholesterol metabolism is a metabolic hallmark in several cancers, beyond the Warburg effect. Reprogrammed cholesterol metabolism has been reported...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jiangnan, Siu, Michelle K.Y., Ngan, Hextan Y. S., Chan, Karen K. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606538/ https://www.ncbi.nlm.nih.gov/pubmed/34820325 http://dx.doi.org/10.3389/fonc.2021.738177

Ejemplares similares

Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
por: Yung, Mingo M. H., et al.
Publicado: (2022)

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer
por: Jiang, Yu-xin, et al.
Publicado: (2022)

Molecular Biomarkers for the Early Detection of Ovarian Cancer
por: Zhang, Ruiqian, et al.
Publicado: (2022)

New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
por: Zhan, Shijie, et al.
Publicado: (2022)

Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer
por: Liu, Michelle X., et al.
Publicado: (2013)

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells
por: Lok, Gabriel T. M., et al.
Publicado: (2011)

Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
por: Wei, Na, et al.
Publicado: (2012)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis
por: Chan, Karen K. L., et al.
Publicado: (2017)

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling
por: Siu, Michelle K. Y., et al.
Publicado: (2020)

Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells
por: Chen, Rain R., et al.
Publicado: (2019)

Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
por: Pyragius, Carmen E., et al.
Publicado: (2013)

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
por: Chan, David W., et al.
Publicado: (2012)

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
por: Siu, Michelle K. Y., et al.
Publicado: (2019)

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
por: Tsoi, Tung Tung, et al.
Publicado: (2020)

Aberrant Metabolism as Inductor of Epigenetic Changes in Breast Cancer: Therapeutic Opportunities
por: Coronel-Hernández, Jossimar, et al.
Publicado: (2021)

Down-regulation of Sox7 is associated with aberrant activation of Wnt/β-catenin signaling in endometrial cancer
por: Chan, David W, et al.
Publicado: (2012)

A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer
por: Helali, Aya El, et al.
Publicado: (2022)

Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy
por: Giacomini, Isabella, et al.
Publicado: (2021)

Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
por: Siu, Michelle K. Y., et al.
Publicado: (2012)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Patient-Initiated Follow-Up in Ovarian Cancer
por: Luk, Hiu Mei, et al.
Publicado: (2023)

The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment
por: Liang, Rui, et al.
Publicado: (2021)

Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression
por: Fung, Frederic K. C., et al.
Publicado: (2012)

Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers
por: Jiang, LiLi, et al.
Publicado: (2010)

Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy
por: Tu, Teng, et al.
Publicado: (2023)

Aberrant cholesterol metabolism in colorectal cancer represents a targetable vulnerability
por: Xie, Jingwu, et al.
Publicado: (2022)

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
por: Wang, Jing-Jing, et al.
Publicado: (2021)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade
por: Yung, Mingo M. H., et al.
Publicado: (2015)

p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation
por: Siu, Michelle K. Y., et al.
Publicado: (2015)

Editorial: Metabolism As a Therapeutic Target
por: Columbano, Amedeo, et al.
Publicado: (2017)

Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer
por: Jiang, Yu-Xin, et al.
Publicado: (2020)

Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
por: Mo, Yulan, et al.
Publicado: (2023)

Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma
por: Shen, Jiayu, et al.
Publicado: (2020)

Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
por: Wei, Na, et al.
Publicado: (2009)

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma
por: Gunda, Venugopal, et al.
Publicado: (2022)

Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer
por: Kumar, Juhi, et al.
Publicado: (2019)

CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target
por: Feng, Xiaojie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gnce3qbalp3odf8vaq5tfn15ug